The Molecular Pathogenesis of Osteosarcoma: A Review
暂无分享,去创建一个
Peter F. M. Choong | P. Choong | C. Dass | D. Myers | Damian E. Myers | Crispin R. Dass | Matthew L. Broadhead | Jonathan C. M. Clark | M. Broadhead | J. C. Clark
[1] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[2] P. Choong,et al. Downregulation of uPAR confirms link in growth and metastasis of osteosarcoma , 2006, Clinical & Experimental Metastasis.
[3] H. Takayanagi. The Role of NFAT in Osteoclast Formation , 2007, Annals of the New York Academy of Sciences.
[4] H. Koeffler,et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. , 1996, Journal of cancer research and clinical oncology.
[5] L. Lau,et al. The CCN family of angiogenic regulators: the integrin connection. , 1999, Experimental cell research.
[6] K. Saja. Regulation of Matrix Metalloproteinases , 2006 .
[7] P. Choong,et al. Osteosarcoma – conventional treatment vs. gene therapy , 2009, Cancer biology & therapy.
[8] D. Campanacci,et al. Expression of transforming growth factor β isoforms in osteosarcoma variants: association of tgfβ1 with high‐grade osteosarcomas , 1998 .
[9] S. Friend,et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma , 1992 .
[10] Jun Luo,et al. The expression and significance of IDH1 and p53 in osteosarcoma , 2010, Journal of experimental & clinical cancer research : CR.
[11] K. Hunter. Ezrin, a key component in tumor metastasis. , 2004, Trends in molecular medicine.
[12] R. Johnson,et al. Hypoxia: A key regulator of angiogenesis in cancer , 2007, Cancer and Metastasis Reviews.
[13] David B. Alexander,et al. The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.
[14] Bin Wang,et al. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo , 2010, Molecular and Cellular Biochemistry.
[15] S. Chakraborti,et al. Regulation of matrix metalloproteinases: An overview , 2003, Molecular and Cellular Biochemistry.
[16] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[18] Han-Soo Kim,et al. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[19] Yong Zhang,et al. Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population , 2011, Medical Oncology.
[20] R. Langer,et al. Troponin I is present in human cartilage and inhibits angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[21] G. Wesolowski,et al. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase , 2003, Cell Death and Differentiation.
[22] J. I. Phillips,et al. Evidence against a role for SV40 in human mesothelioma. , 2005, Cancer research.
[23] S. Hwang,et al. Growth and development and other risk factors for osteosarcoma in children and young adults. , 1997, International journal of epidemiology.
[24] M. Fernö,et al. Urokinase‐plasminogen‐activator levels and prognosis in 69 soft‐tissue sarcomas , 1996, International journal of cancer.
[25] Kozo Nakamura,et al. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system , 2005, Immunological reviews.
[26] P. Houghton,et al. Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts , 2010 .
[27] S. Ferrari,et al. Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] O. Fromigué,et al. Blockade of the RhoA-JNK-c-Jun-MMP2 Cascade by Atorvastatin Reduces Osteosarcoma Cell Invasion* , 2008, Journal of Biological Chemistry.
[29] Sanjiv Sam Gambhir,et al. 18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation , 2008, Cancer biology & therapy.
[30] A. Uchida,et al. Effect of retinoblastoma tumor suppressor gene expression on chemosensitivity of human osteosarcoma cell lines. , 2003, Oncology reports.
[31] F. Higashino,et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] G. Melino,et al. Parathyroid hormone‐related protein confers chemoresistance by blocking apoptosis signaling via death receptors and mitochondria , 2009, International journal of cancer.
[33] S. Coniglio,et al. Rac1 Protects Epithelial Cells against Anoikis* , 2001, The Journal of Biological Chemistry.
[34] E. T. Ek,et al. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis , 2007, Cancer Gene Therapy.
[35] G. Castellani,et al. Mechanisms of gene amplification and evidence of coamplification in drug‐resistant human osteosarcoma cell lines , 2009, Genes, chromosomes & cancer.
[36] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[37] P. Choong,et al. Osteosarcoma treatment: state of the art , 2009, Cancer and Metastasis Reviews.
[38] R. Gutiérrez,et al. Angiogenesis: an update. , 1994, Histology and histopathology.
[39] C. Carman,et al. Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.
[40] S. de Jong,et al. The insulin‐like growth factor system and sarcomas , 2009, The Journal of pathology.
[41] L. Hofbauer,et al. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. , 1998, European journal of endocrinology.
[42] P. Terrier,et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] P. Picci,et al. C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.
[44] P. Choong,et al. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway , 2008, Molecular Cancer Therapeutics.
[45] F. Dutra,et al. Osteosarcoma induced by beryllium oxide. , 1950, The American journal of pathology.
[46] S. Cook,et al. Extracellular Signal-regulated Kinases 1/2 Are Serum-stimulated “BimEL Kinases” That Bind to the BH3-only Protein BimEL Causing Its Phosphorylation and Turnover* , 2004, Journal of Biological Chemistry.
[47] D. Fitzwilliams. Popliteal Aneurysm , 1937, Proceedings of the Royal Society of Medicine.
[48] Hisataka Yasuda,et al. Transforming Growth Factor β Affects Osteoclast Differentiation via Direct and Indirect Actions , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[49] F. Cogé,et al. The role of the matrix metalloproteinases during in vitro vessel formation , 2004, Angiogenesis.
[50] M. Dembo,et al. Cell movement is guided by the rigidity of the substrate. , 2000, Biophysical journal.
[51] P. Picci,et al. Prognostic Value of CCN3 in Osteosarcoma , 2008, Clinical Cancer Research.
[52] G. Ottaviani,et al. The epidemiology of osteosarcoma. , 2009, Cancer treatment and research.
[53] K. Ishizaki,et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. , 1994, Cancer research.
[54] H. Saya,et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis , 2010, Oncogene.
[55] V. Castronovo,et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. , 2007, Cancer research.
[56] D. Mercola,et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. , 1990, Oncogene.
[57] J. Davies,et al. Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.
[58] Yong Zhang,et al. Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study , 2010, BMC Cancer.
[59] D. Bar-Sagi,et al. Redox-dependent downregulation of Rho by Rac , 2003, Nature Cell Biology.
[60] S. Stoch,et al. Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy , 2008, Clinical pharmacology and therapeutics.
[61] Peter Carmeliet,et al. VEGF as a Key Mediator of Angiogenesis in Cancer , 2005, Oncology.
[62] M. Pearce,et al. Stature of young people with malignant bone tumors , 2004, Pediatric blood & cancer.
[63] Lena Claesson-Welsh,et al. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.
[64] A. Mazabraud. [Experimental production of bone sarcomas in the rabbit by a single local injection of beryllium]. , 1975, Bulletin du cancer.
[65] E. Ruoslahti,et al. A Mitochondrial Protein, Bit1, Mediates Apoptosis Regulated by Integrins and Groucho/TLE Corepressors , 2005, Cell.
[66] H. Dvorak,et al. VEGF-A and the induction of pathological angiogenesis. , 2007, Annual review of pathology.
[67] A. Greenspan,et al. Differential Diagnosis in Orthopaedic Oncology , 2006 .
[68] M. Takigawa,et al. Effects of CTGF/Hcs24, a hypertrophic chondrocyte‐specific gene product, on the proliferation and differentiation of osteoblastic cells in vitro , 2000, Journal of cellular physiology.
[69] T. Martin,et al. Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. , 1988, The Journal of endocrinology.
[70] H. Donninger,et al. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. , 2009, The American journal of pathology.
[71] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[72] R. Khosravi‐Far,et al. Regulation of tumor angiogenesis by thrombospondin-1. , 2006, Biochimica et biophysica acta.
[73] A. Franchi,et al. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton , 1998, Virchows Archiv.
[74] Sakae Tanaka,et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption , 1996, Nature.
[75] A. Tsatsakis,et al. Parathyroid hormone (PTH) peptides through the regulation of hyaluronan metabolism affect osteosarcoma cell migration , 2010, IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology.
[76] M. Gebhardt,et al. Biology and therapeutic advances for pediatric osteosarcoma. , 2004, The oncologist.
[77] J. Zajac,et al. Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106-01) cell line results in growth inhibition. , 2002, Bone.
[78] G. Thurston,et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting , 2007, Proceedings of the National Academy of Sciences.
[79] Stephen M Hewitt,et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis , 2004, Nature Medicine.
[80] A. Paulino,et al. SECONDARY NEOPLASMS AFTER RADIOTHERAPY FOR A CHILDHOOD SOLID TUMOR , 2005, Pediatric hematology and oncology.
[81] Carl W. Miller,et al. Integration of SV40 in human osteosarcoma DNA , 1998, Oncogene.
[82] M. Freedman,et al. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin , 2006, Cancer Gene Therapy.
[83] F. Bertoni,et al. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma. , 2004, Pathology, research and practice.
[84] L. Helman,et al. Autocrine Transforming Growth Factor-β Growth Pathway in Murine Osteosarcoma Cell Lines Associated with Inability to Affect Phosphorylation of Retinoblastoma Protein , 2000, Sarcoma.
[85] P. Leavey,et al. Lack of Prognostic Significance of Intratumoral Angiogenesis in Nonmetastatic Osteosarcoma , 2001, Journal of pediatric hematology/oncology.
[86] A. Polednak. Bone cancer among female radium dial workers. Latency periods and incidence rates by time after exposure: brief communication. , 1978, Journal of the National Cancer Institute.
[87] H. Fujioka,et al. Expression of VEGF and its receptors and angiogenesis in bone and soft tissue tumors. , 2006, Anticancer research.
[88] M. Ladanyi,et al. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids , 2004, The Lancet.
[89] Peter F M Choong,et al. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.
[90] H. Dvorak,et al. Angiogenesis: update 2005 , 2005, Journal of thrombosis and haemostasis : JTH.
[91] G. Bacci,et al. Height as a risk factor in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] J. Chirgwin,et al. Molecular biology of bone metastasis. , 2008, Molecular cancer therapeutics.
[93] E. Engels. Cancer risk associated with receipt of vaccines contaminated with simian virus 40: epidemiologic research , 2005, Expert review of vaccines.
[94] R. O’Keefe,et al. Molecular biology and therapeutics in musculoskeletal oncology. , 2009, The Journal of bone and joint surgery. American volume.
[95] David M. Thomas,et al. RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer , 2007, Cancer and Metastasis Reviews.
[96] A. Huvos,et al. Over‐expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma , 2007, International journal of cancer.
[97] Zhaoming Ye,et al. Enhancement Effect of Adenovirus-Mediated Antisense c-myc and Caffeine on the Cytotoxicity of Cisplatin in Osteosarcoma Cell Lines , 2009, Chemotherapy.
[98] E. Wagner,et al. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. , 1995, Cancer research.
[99] Michael R. Green,et al. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome , 2007, Journal of Molecular Medicine.
[100] P. Choong,et al. Cancer cell apoptotic pathways mediated by PEDF: prospects for therapy. , 2009, Trends in molecular medicine.
[101] A. Teti,et al. Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases. , 2008, Anti-cancer agents in medicinal chemistry.
[102] P. Choong,et al. Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours , 2010, Cancer Cell International.
[103] S. Bielack,et al. Determination of the prognostic value of loss of heterozygosity at the retinoblastoma gene in osteosarcoma. , 2007, International journal of oncology.
[104] Ak SharmaCol,et al. Campbell's Operative Orthopaedics , 2004 .
[105] Taro Matsumoto,et al. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. , 2006, Journal of atherosclerosis and thrombosis.
[106] P. Choong,et al. The pathophysiological role of PEDF in bone diseases. , 2010, Current molecular medicine.
[107] J. Chirgwin,et al. Transforming growth factor-beta in osteolytic breast cancer bone metastases. , 2003, Clinical orthopaedics and related research.
[108] A. Togari,et al. Osteoclast Differentiation Factor in Human Osteosarcoma Cell Line , 2000, Journal of immunoassay.
[109] R. Kerbel,et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. , 1999, Biochemical and biophysical research communications.
[110] A. Sereno,et al. Combination of Two Insulin-Like Growth Factor-I Receptor Inhibitory Antibodies Targeting Distinct Epitopes Leads to an Enhanced Antitumor Response , 2010, Molecular Cancer Therapeutics.
[111] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[112] F. Watt,et al. Switch from αvβ5 to αvβ6 integrin expression protects squamous cell carcinomas from anoikis , 2004, The Journal of cell biology.
[113] J. German. Bloom's syndrome , 1995 .
[114] M. Ladanyi,et al. p53 and MDM2 alterations in osteosarcomas , 1997, Cancer.
[115] G. Watkins,et al. Decreased Pigment Epithelium–Derived Factor Expression in Human Breast Cancer Progression , 2006, Clinical Cancer Research.
[116] R. Monnat,et al. Mutator phenotype of Werner syndrome is characterized by extensive deletions. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[117] Carl W. Miller,et al. Alterations of thep53, Rb andMDM2 genes in osteosarcoms , 2005, Journal of Cancer Research and Clinical Oncology.
[118] J. Vandenbroucke,et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma , 2003, European Journal of Human Genetics.
[119] J. Schlessinger. New Roles for Src Kinases in Control of Cell Survival and Angiogenesis , 2000, Cell.
[120] J. German,et al. Bloom's syndrome. III. Analysis of the chromosome aberration characteristic of this disorder , 2004, Chromosoma.
[121] Kenneth M. Yamada,et al. Cell–matrix adhesion , 2007, Journal of cellular physiology.
[122] G. Bacci,et al. Radiation-Induced Osteosarcoma Arising 20 years after the Treatment of Ewing's Sarcoma , 2003, Tumori.
[123] S. Itohara,et al. Contribution of host MMP‐2 and MMP‐9 to promote tumor vascularization and invasion of malignant keratinocytes , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[124] M. Rosemann,et al. Genomic Alterations and Allelic Imbalances Are Strong Prognostic Predictors in Osteosarcoma , 2010, Clinical Cancer Research.
[125] N. Chandar,et al. Inactivation of p53 gene in human and murine osteosarcoma cells. , 1992, British Journal of Cancer.
[126] P. Choong,et al. Localization of Pigment Epithelium-Derived Factor in Growing Mouse Bone , 2005, Calcified Tissue International.
[127] E. T. Ek,et al. PEDF‐derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[128] P. Choong,et al. The urokinase plasminogen activator receptor as a gene therapy target for cancer. , 2007, Trends in biotechnology.
[129] J. Chirgwin,et al. Skeletal metastases: Decreasing tumor burden by targeting the bone microenvironment , 2007, Journal of cellular biochemistry.
[130] B. Fuchs,et al. Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis , 2008, Molecular carcinogenesis.
[131] H. S. Kim,et al. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma , 2000, International Orthopaedics.
[132] P. Picci,et al. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma , 1999, International journal of cancer.
[133] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] Cynthia A. Reinhart-King,et al. Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.
[135] E. T. Ek,et al. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor , 2007, Clinical & Experimental Metastasis.